282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
What does it mean to be Zepbound?
November 9, 202337m 1s
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. We also discuss the approval of Eli Lilly’s curiously named treatment for obesity, the latest implosion for a promising biotech company, and some news in the world of shareholder activism.
To keep up between podcast episodes, here’s where you can subscribe to our biotech newsletter, The Readout.